OKUR NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

OnKure Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 4.12 USD
-1.9% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 9.3% above the Trend Line and sits at 63.7% of its 52-week range. The latest completed week returned -1.9%, after a -8.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 31/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 40 out of 100
Latest Close 4.12 USD 24 Jul 2026
1W Return -1.9% latest completed week
4W Return -8.4% short-term follow-through
12W Return -12.9% quarterly tape
Trend Breadth 67.3% 35 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • The trend backdrop is active with a 20-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -1.9% Latest completed week; four-week move -8.4%. Indicator stack 82/0 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 31/100 conviction; expected move 11.4%. News sentiment 53/100 41 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 9.3% above the Trend Line and sits at 63.7% of its 52-week range. The latest completed week returned -1.9%, after a -8.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7112-week average 0.74

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.71Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -8.4% over four weeks, -12.9% over 12 weeks, and 78.4% over one year. The current trend has remained active for 20 consecutive weeks.

Performance by holding period

1W-1.9%
4W-8.4%
12W-12.9%
26W40.6%
52W78.4%
Active trend streak20 weeks
Active weeks in one year35
Trend breadth67.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.30Latest activity-pressure read.
Pressure change-642.0%Four-week change in activity pressure.
Leadership13.58Latest relative-leadership reading.
RS change-42.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 64% Model confidence 61%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength47/100Blend of value, momentum, and quality. Underlying universe rank 54; rank 1 is best.
Value48/100Relative valuation strength. Underlying universe rank 53; rank 1 is best.
Quality47/100Profitability and accounting quality. Underlying universe rank 54; rank 1 is best.
Momentum48/100Medium-term price momentum. Underlying universe rank 53; rank 1 is best.
Growth48/100Revenue and earnings growth. Underlying universe rank 53; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-30.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-87.7%
Net share repurchases relative to market value.
Shareholder yield
-87.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

OKUR shows mixed options pressure with a 31/100 conviction score, put-call volume ratio of n/a, expected move of 11.4%, and Sharemaestro trend signal active.

Conviction31/100
Expected move11.4%
Put/call volume
Pressure0
Speculation0
Volatility72
Trend agreement90
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 41 relevant articles.

9 positive · 29 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move11.4%Nearest-chain priced movement where available.
52-week drawdown-23.4%Distance below the 52-week high.
13-week volatility12.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+33.2%Week of 22 May.
Worst week-19.2%Week of 15 May.
Latest week-1.9%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains4
Flat weeks0
Modest losses6
Sharp losses7
Recent vol12.0%13-week weekly-return volatility.
Base vol10.5%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew9.4% / -6.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape47/100

Trend, activity pressure, participation, and risk combine to a 47/100 tape read.

 Indicator analysis78/100

Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 11/12.

Activity pressure 0.71; No reversal markers Factors46/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100; Small Cap Core rank 55 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options56/100

OKUR shows mixed options pressure with a 31/100 conviction score, put-call volume ratio of n/a, expected move of 11.4%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 11.4% Sentiment53/100

Weighted news tone is neutral across 41 relevant articles.

Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20264.12 USD-1.9%3.77 USD4.98 USD-0.3013.58628.7KOn
17 Jul 20264.20 USD-1.9%3.72 USD4.99 USD-0.1614.74494.5KOn
10 Jul 20264.28 USD-6.6%3.69 USD5.00 USD-0.0612.841.3MOn
3 Jul 20264.58 USD1.8%3.64 USD5.01 USD-0.0323.561.3MOn
26 Jun 20264.50 USD0.4%3.59 USD5.01 USD0.0623.424.6MOn
19 Jun 20264.48 USD6.7%3.54 USD5.02 USD0.0518.212.4MOn
12 Jun 20264.20 USD0.2%3.48 USD5.02 USD0.1514.44993.9KOn
5 Jun 20264.19 USD-0.2%3.45 USD5.03 USD0.1717.153.1MOn
29 May 20264.20 USD-0.2%3.40 USD5.04 USD0.2512.35726.5KOn
22 May 20264.21 USD33.2%3.38 USD5.05 USD0.5116.231.2MOn
15 May 20263.16 USD-19.2%3.35 USD5.06 USD0.75-11.15821.6KOn
8 May 20263.91 USD-17.3%3.33 USD5.09 USD1.169.84577.0KOn
1 May 20264.73 USD-1.5%3.31 USD5.10 USD1.3941.02612.8KOn
24 Apr 20264.80 USD-4.0%3.24 USD5.10 USD1.5146.39450.3KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.